Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Janssen Pharmaceutical Companies of Johnson & Johnson - Expanding the therapeutic opportunities in advanced prostate cancer

nmCRPC: Practical identification and current management of patients with nmCRPC

Date

29 Sep 2019

Session

Janssen Pharmaceutical Companies of Johnson & Johnson - Expanding the therapeutic opportunities in advanced prostate cancer

Presenters

Laura-Maria Krabbe

Authors

L. Krabbe

Author affiliations

  • Urology, University Hospital of Münster, 48149 - Münster/DE
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings